• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较未经校正和校正凝血酶原时间与活化部分凝血活酶时间检测法的凝血波形分析,以评估直接口服抗凝剂的体外效应。

Comparison of clot waveform analysis with or without adjustment between prothrombin time and activated partial thromboplastin time assays to assess in vitro effects of direct oral anticoagulants.

机构信息

Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.

Clinical Laboratory, Keio University Hospital, Tokyo, Japan.

出版信息

Clin Chim Acta. 2024 Aug 15;562:119887. doi: 10.1016/j.cca.2024.119887. Epub 2024 Jul 24.

DOI:10.1016/j.cca.2024.119887
PMID:39059480
Abstract

BACKGROUND

Clot waveform analysis (CWA) reportedly enhances the interpretation of clotting time measurement. This study aimed to compare CWA between prothrombin time (PT) and activated partial thromboplastin time (APTT) assays for better understanding how to apply CWA for assessing effects of direct oral anticoagulants (DOACs).

METHODS

Samples were prepared by spiking plasma with rivaroxaban, apixaban, edoxaban, or dabigatran. To compensate the influence of fibrinogen, CWA parameters were adjusted by unifying maximum changes in transmittance in clotting reaction curves detected by the optical system.

RESULTS

Non-adjusted PT-CWA parameters unexpectedly rose at low drug concentrations but declined at high drug concentrations while adjusted PT-CWA parameters exhibited dose-dependent decrease. Both non-adjusted and adjusted APTT-CWA parameters showed dose-dependent decrease. Adjusted CWA parameters were applicable to Hill plot analysis. All DOACs exhibited Hill coefficients indicating positively cooperative effects regarding most adjusted PT-CWA parameters. Regarding adjusted APTT-CWA parameters, rivaroxaban, apixaban, and edoxaban exhibited Hill coefficients indicating no or negatively cooperative effects. The observed differences between PT-CWA and APTT-CWA suggested the implication of thrombin positive feedback in DOAC effects.

CONCLUSION

The results revealed distinct features of DOAC effects in extrinsic and intrinsic pathways. To ascertain the clinical implication, further studies using clinical samples are needed.

摘要

背景

据报道,凝块波形分析(CWA)可增强对凝血时间测量的解释。本研究旨在比较凝血酶原时间(PT)和活化部分凝血活酶时间(APTT)测定中的 CWA,以更好地了解如何应用 CWA 评估直接口服抗凝剂(DOAC)的作用。

方法

通过向血浆中添加利伐沙班、阿哌沙班、依度沙班或达比加群来制备样品。为了补偿纤维蛋白原的影响,通过统一光学系统检测到的凝血反应曲线中透光率的最大变化来调整 CWA 参数。

结果

未经调整的 PT-CWA 参数在低药物浓度下意外升高,但在高药物浓度下下降,而调整后的 PT-CWA 参数则呈剂量依赖性下降。未经调整和调整后的 APTT-CWA 参数均呈剂量依赖性下降。调整后的 CWA 参数适用于 Hill 图分析。所有 DOAC 均表现出表明对大多数调整后的 PT-CWA 参数具有正协同作用的 Hill 系数。关于调整后的 APTT-CWA 参数,利伐沙班、阿哌沙班和依度沙班表现出表明无协同作用或负协同作用的 Hill 系数。PT-CWA 和 APTT-CWA 之间观察到的差异表明 DOAC 作用中存在凝血酶正反馈。

结论

研究结果揭示了 DOAC 在外源性和内源性途径中的作用的独特特征。为了确定临床意义,需要使用临床样本进行进一步研究。

相似文献

1
Comparison of clot waveform analysis with or without adjustment between prothrombin time and activated partial thromboplastin time assays to assess in vitro effects of direct oral anticoagulants.比较未经校正和校正凝血酶原时间与活化部分凝血活酶时间检测法的凝血波形分析,以评估直接口服抗凝剂的体外效应。
Clin Chim Acta. 2024 Aug 15;562:119887. doi: 10.1016/j.cca.2024.119887. Epub 2024 Jul 24.
2
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.在接受直接口服抗凝剂治疗的患者中,凝血筛选试验与特定检测方法的可比性较差:一项多中心/多平台研究的结果。
J Thromb Haemost. 2016 Nov;14(11):2194-2201. doi: 10.1111/jth.13486. Epub 2016 Oct 15.
3
Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.通过凝块波形分析评估直接凝血酶抑制剂和活化因子 X 抑制剂的体外效应。
J Clin Pathol. 2019 Mar;72(3):244-250. doi: 10.1136/jclinpath-2018-205517. Epub 2018 Dec 5.
4
Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.改良血栓波形分析在抗因子 IXa/因子 X 双特异性抗体emicizumab 存在的情况下测量血浆凝血潜能。
J Thromb Haemost. 2018 Jun;16(6):1078-1088. doi: 10.1111/jth.14022. Epub 2018 May 13.
5
Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.抗Xa因子直接口服抗凝剂阿哌沙班、依度沙班和利伐沙班对凝血检测影响的比较。
Int J Lab Hematol. 2016 Oct;38(5):505-13. doi: 10.1111/ijlh.12528. Epub 2016 Jun 6.
6
Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls.在接受依度沙班治疗的患者和健康对照中比较凝血块波形分析和FibWave的分析性能。
Res Pract Thromb Haemost. 2022 Nov 4;6(7):e12804. doi: 10.1002/rth2.12804. eCollection 2022 Oct.
7
Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors.通过血栓波形分析对依赖抗凝血酶的抗凝剂进行特征分析,以潜在地区分它们与靶向活化凝血因子的抗凝血酶非依赖性抑制剂。
J Clin Pathol. 2021 Apr;74(4):251-256. doi: 10.1136/jclinpath-2020-206835. Epub 2020 Aug 12.
8
Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.实验室间直接口服抗凝剂测量的变异性:来自外部质量评估计划的结果。
J Thromb Haemost. 2018 Mar;16(3):565-570. doi: 10.1111/jth.13949. Epub 2018 Jan 29.
9
Coagulation Status Using Clot Wave Analysis in Patients With Prolonged Immobilization.长时间制动患者凝血状态的血栓波分析
Cureus. 2024 Jan 1;16(1):e51483. doi: 10.7759/cureus.51483. eCollection 2024 Jan.
10
Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.基于凝固试验中的凝块波形分析和酶动力学揭示了双价直接凝血酶抑制剂水蛭素和比伐卢定的独特特征。
J Clin Pathol. 2019 Dec;72(12):817-824. doi: 10.1136/jclinpath-2019-205922. Epub 2019 Jul 31.

引用本文的文献

1
Deep learning model for screening causes of activated partial thromboplastin time prolongation using clot waveform analysis at multiple wavelengths.基于多波长凝血波形分析的深度学习模型用于筛查活化部分凝血活酶时间延长的原因
Sci Rep. 2025 Sep 2;15(1):32336. doi: 10.1038/s41598-025-15089-3.